Research programme: spinal muscular atrophy therapeutics - PTC Therapeutics

Drug Profile

Research programme: spinal muscular atrophy therapeutics - PTC Therapeutics

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PTC Therapeutics
  • Developer PTC Therapeutics; Roche; Spinal Muscular Atrophy Foundation
  • Class Small molecules
  • Mechanism of Action Survival of motor neuron 1 protein stimulants; Survival of motor neuron 2 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Spinal muscular atrophy

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Spinal-muscular-atrophy in USA (PO)
  • 18 Aug 2014 Pharmacodynamics data from in vitro and preclinical studies in Spinal muscular atrophy released by PTC Therapeutics and Roche
  • 12 Aug 2013 Preclinical trials in Spinal muscular atrophy in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top